PharmaCyte Biotech (PMCB) Short Interest Ratio & Short Volume → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free PMCB Stock Alerts $2.11 -0.01 (-0.47%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial Media PharmaCyte Biotech Short Interest DataCurrent Short Volume18,200 sharesPrevious Short Volume45,700 sharesChange Vs. Previous Month-60.18%Dollar Volume Sold Short$38,402.00Short Interest Ratio / Days to Cover0.7Last Record DateApril 15, 2024Outstanding Shares8,450,000 sharesFloat Size7,610,000 sharesShort Percent of Float0.24%Today's Trading Volume5,644 sharesAverage Trading Volume17,104 sharesToday's Volume Vs. Average33% Short Selling PharmaCyte Biotech ? Sign up to receive the latest short interest report for PharmaCyte Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPMCB Short Interest Over TimePMCB Days to Cover Over TimePMCB Percentage of Float Shorted Over Time Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> PharmaCyte Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202418,200 shares $38,402.00 -60.2%0.2%0.7 $2.11 3/31/202445,700 shares $108,309.00 +501.3%0.6%1.8 $2.37 3/15/20247,600 shares $14,820.00 -68.7%0.1%0.3 $1.95 2/29/202424,300 shares $51,030.00 -4.3%0.3%1.6 $2.10 2/15/202425,400 shares $53,086.00 -19.4%0.4%1.6 $2.09 1/31/202431,500 shares $68,985.00 +18.9%0.4%2 $2.19 Get the Latest News and Ratings for PMCB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. 1/15/202426,500 shares $59,625.00 -14.8%0.4%1.5 $2.25 12/31/202331,100 shares $67,176.00 +15.2%0.5%1.8 $2.16 12/15/202327,000 shares $58,050.00 +2.7%0.4%1.5 $2.15 11/30/202326,300 shares $59,438.00 -9.6%0.4%1.4 $2.26 11/15/202329,100 shares $59,364.00 -12.6%0.4%1.5 $2.04 10/31/202333,300 shares $70,596.00 -17.4%0.5%1.6 $2.12 10/15/202340,300 shares $84,227.00 -12.2%0.6%1.9 $2.09 9/30/202345,900 shares $96,390.00 -27.8%0.7%2.1 $2.10 9/15/202363,600 shares $159,000.00 +27.0%0.9%3 $2.50 8/31/202350,100 shares $122,745.00 -4.0%0.6%1.9 $2.45 6/30/202139,300 shares $424.44 +48.9%N/A0 $0.01 6/15/202126,400 shares $298.32 -27.7%N/A0 $0.01 5/28/202136,500 shares $463.55 -69.0%N/A0 $0.01 5/14/2021117,600 shares $1,481.76 +113.4%N/A0 $0.01 4/30/202155,100 shares $936.70 -72.2%N/A0 $0.02 4/15/2021198,000 shares $3,245.22 +11.1%N/A0 $0.02 3/31/2021178,200 shares $3,073.95 +11.0%N/A0 $0.02 3/15/2021160,500 shares $3,370.50 +817.1%N/A0 $0.02 2/26/202117,500 shares $507.50 -93.3%N/A0 $0.03 2/12/2021260,800 shares $4,824.80 +327.5%N/A0 $0.02 1/29/202161,000 shares $1,037.00 +42.9%N/A0 $0.02 1/15/202128,200 shares $383.52 -69.7%N/A0 $0.01 12/31/202041,700 shares $271.05 +47.9%N/A0 $0.01 12/15/202028,200 shares $155.10 -69.7%N/A0 $0.01 11/30/202093,200 shares $559.20 +486.2%N/A0 $0.01 11/15/202015,900 shares $108.12 No ChangeN/A0 $0.01 10/30/202015,900 shares $141.51 +13.6%N/A0 $0.01 10/15/202014,000 shares $131.60 -74.0%N/A0 $0.01 9/30/202053,900 shares $916.30 +20.0%N/A0 $0.02 9/15/202044,900 shares $493.90 -58.9%N/A0 $0.01 8/31/2020109,300 shares $1,300.67 +680.7%N/A0 $0.01 8/14/202014,000 shares $196.00 -95.6%N/A0 $0.01 7/31/2020319,600 shares $4,474.40 +413.0%N/A0 $0.01 7/15/202062,300 shares $1,264.69 -77.0%N/A0 $0.02They say it’s ‘unstoppable’ – How I made 43,509% (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. PMCB Short Interest - Frequently Asked Questions What is PharmaCyte Biotech's current short interest? Short interest is the volume of PharmaCyte Biotech shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 18,200 shares of PMCB short. 0.24% of PharmaCyte Biotech's shares are currently sold short. Learn More on PharmaCyte Biotech's current short interest. What is a good short interest ratio for PharmaCyte Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PMCB shares currently have a short interest ratio of 1.0. Learn More on PharmaCyte Biotech's short interest ratio. What is a good short interest percentage for PharmaCyte Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.24% of PharmaCyte Biotech's floating shares are currently sold short. Is PharmaCyte Biotech's short interest increasing or decreasing? PharmaCyte Biotech saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 18,200 shares, a drop of 60.2% from the previous total of 45,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is PharmaCyte Biotech's float size? PharmaCyte Biotech currently has issued a total of 8,450,000 shares. Some of PharmaCyte Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. PharmaCyte Biotech currently has a public float of 7,610,000 shares. How does PharmaCyte Biotech's short interest compare to its competitors? 0.24% of PharmaCyte Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to PharmaCyte Biotech: Aptose Biosciences Inc. (0.59%), Evaxion Biotech A/S (0.92%), Senti Biosciences, Inc. (0.60%), ZIVO Bioscience, Inc. (4.24%), Coeptis Therapeutics Holdings, Inc. (0.66%), BioCardia, Inc. (1.01%), Pluri Inc. (0.91%), Organovo Holdings, Inc. (1.49%), Genetic Technologies Limited (0.41%), Windtree Therapeutics, Inc. (0.90%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short PharmaCyte Biotech stock? Short selling PMCB is an investing strategy that aims to generate trading profit from PharmaCyte Biotech as its price is falling. PMCB shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against PharmaCyte Biotech? A short squeeze for PharmaCyte Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PMCB, which in turn drives the price of the stock up even further. How often is PharmaCyte Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PMCB, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Aptose Biosciences Short Squeeze Evaxion Biotech A/S Short Squeeze Senti Biosciences Short Squeeze ZIVO Bioscience Short Squeeze Coeptis Therapeutics Short Squeeze BioCardia Short Squeeze Pluri Short Squeeze Organovo Short Squeeze Genetic Technologies Short Squeeze Windtree Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PMCB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press